Anal Cancer - Pipeline Review, H2 2015

Description: Anal Cancer - Pipeline Review, H2 2015

Summary


This report provides comprehensive information on the therapeutic development for Anal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anal Cancer and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updates following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Anal Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Anal Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Anal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Anal Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Anal Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Anal Cancer pipeline depth and focus of
Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Contents:
- List of Tables
- List of Figures
- Introduction

REPORT COVERAGE
- Anal Cancer Overview
- Therapeutics Development
- Pipeline Products for Anal Cancer - Overview
- Pipeline Products for Anal Cancer - Comparative Analysis
- Anal Cancer - Therapeutics under Development by Companies
- Anal Cancer - Therapeutics under Investigation by Universities/Institutes
- Anal Cancer - Pipeline Products Glance
- Clinical Stage Products
- Anal Cancer - Products under Development by Companies
- Anal Cancer - Products under Investigation by Universities/Institutes
- Anal Cancer - Companies Involved in Therapeutics Development
- Advaxis, Inc.
- Amgen Inc.
- Eli Lilly and Company
- ISA Pharmaceuticals B.V.
- MedImmune, LLC
- Novartis AG
- Sun Pharma Advanced Research Company Ltd.
- Anal Cancer - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
Assessment by Molecule Type

Drug Profiles

axalimogene filolisbac - Drug Profile
Product Description
Mechanism of Action
R&D Progress

Cell Therapy for HPV Associated Cancers - Drug Profile
Product Description
Mechanism of Action
R&D Progress

durvalumab + tremelimumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress

ISA-101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress

paclitaxel albumin free - Drug Profile
Product Description
Mechanism of Action
R&D Progress

panitumumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress

PDR-001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress

prexasertib - Drug Profile
Product Description
Mechanism of Action

R&D Progress

Anal Cancer - Recent Pipeline Updates

Anal Cancer - Dormant Projects

Anal Cancer - Product Development Milestones

Featured News & Press Releases

Apr 06, 2015: Advaxis and RTOG Foundation to Collaborate on Pivotal Phase 2/3 Clinical Trial of ADXS-HPV in Anal Cancer

Oct 15, 2014: Advaxis Provides Clinical Update for Phase 1/2 Trial of ADXS-HPV Immunotherapy Product Candidate in Anal Cancer

Feb 11, 2014: SynCo Bio Partners Expands Live Microbial Product Experience

Jun 24, 2013: Advaxis Requests Orphan Drug Designation For Treatment Of HPV-Associated Anal Cancer with ADXS-HPV

Apr 22, 2013: Advaxis Announces First Patient Dosed In Brown University Sponsored Phase I/II Anal Cancer Study Of ADXS-HPV

Mar 03, 2013: Advaxis Provides Update On ADXS-HPV Cancer Immunotherapy

Feb 19, 2013: Advaxis Announces Brown University Oncology Group To Conduct Phase I/II Trial Of ADXS-HPV In Anal Cancer

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Anal Cancer, H2 2015

Number of Products under Development for Anal Cancer - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Number of Products under Investigation by Universities/Institutes, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Products under Development by Companies, H2 2015

Products under Investigation by Universities/Institutes, H2 2015
Anal Cancer - Pipeline by Advaxis, Inc., H2 2015
Anal Cancer - Pipeline by Amgen Inc., H2 2015
Anal Cancer - Pipeline by Eli Lilly and Company, H2 2015
Anal Cancer - Pipeline by ISA Pharmaceuticals B.V., H2 2015
Anal Cancer - Pipeline by MedImmune, LLC, H2 2015
Anal Cancer - Pipeline by Novartis AG, H2 2015
Anal Cancer - Pipeline by Sun Pharma Advanced Research Company Ltd., H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Anal Cancer Therapeutics - Recent Pipeline Updates, H2 2015
Anal Cancer - Dormant Projects, H2 2015
List of Figures
Number of Products under Development for Anal Cancer, H2 2015
Number of Products under Development for Anal Cancer - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Anal Cancer - Pipeline Review, H2 2015
Web Address: http://www.researchandmarkets.com/reports/3440623/
Office Code: SCD2I6U8

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Single User: Electronic (PDF)</td>
<td>USD 2000</td>
</tr>
<tr>
<td>Site License: Electronic (PDF)</td>
<td>USD 4000</td>
</tr>
<tr>
<td>Enterprise Wide: Electronic (PDF)</td>
<td>USD 6000</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [ ] Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof
First Name: ___________________________________ Last Name: ___________________________________
Email Address: * ___________________________________
Job Title: ___________________________________
Organisation: ___________________________________
Address: ___________________________________
City: ___________________________________
Postal / Zip Code: ___________________________________
Country: ___________________________________
Phone Number: ___________________________________
Fax Number: ___________________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp